Novoic develops AI-enabled software for earlier detection of Alzheimer's disease and subtle cognitive impairment using speech-based cognitive testing. Their technology focuses on scalable access to early detection for effective treatment, supporting underserved communities across 50+ medical centers alongside the Alzheimer's Disease Neuroimaging Initiative.

Novoic's solutions include automated, self-assessment audio-verbal tests that work on any smart device via a browser-based approach. Their AI models accurately detect mild cognitive impairment and differential diagnosis of neuropathology, including prediction of amyloid PET positivity. They offer tools like the Storyteller for automated testing, Dashboard for patient funnel management, and Speech API for custom integration.

The company's algorithms are validated through clinical trials with biomarker-confirmed Alzheimer's patients and diverse datasets to ensure robustness and equity. Novoic emphasizes data privacy, security, and quality with integrated HIPAA/GDPR compliance, automated backups, and gold-standard security protocols built into their software.

Novoic collaborates with over 50 top institutions in the US and internationally to implement early Alzheimer's detection technologies, improving patient selection and providing scalable screening and monitoring solutions in clinical research and care.